Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Current Liabilities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Total Current Liabilities for 15 consecutive years, with $65.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 2.37% to $65.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $65.6 million, a 2.37% increase, with the full-year FY2025 number at $63.1 million, up 1.34% from a year prior.
  • Total Current Liabilities was $65.6 million for Q4 2025 at Aytu Biopharma, down from $66.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $109.4 million in Q2 2021 to a low of $61.3 million in Q3 2024.
  • A 5-year average of $74.4 million and a median of $67.1 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 355.67% in 2021, then crashed 41.12% in 2022.
  • Aytu Biopharma's Total Current Liabilities stood at $100.6 million in 2021, then crashed by 33.23% to $67.1 million in 2022, then decreased by 4.41% to $64.2 million in 2023, then dropped by 0.22% to $64.0 million in 2024, then rose by 2.37% to $65.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Total Current Liabilities are $65.6 million (Q4 2025), $66.0 million (Q3 2025), and $63.1 million (Q2 2025).